Table 3.
Variables correlating with inferior OS in the CCD cohort (n = 87)
|
Variable |
n (%) | Univariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Age > 60 y | 50 (57) | 1.3 | 0.6-2.7 | .54 | |||
| Stage III/IV | 72 (83) | 2.7 | 0.6-11.4 | .18 | |||
| Performance: ECOG PS ≥ 2 | 10 (11) | 3.6 | 1.6-8.0 | .002 | 19.2 | 2.8-133.0 | .003 |
| LDH elevated | 53 (61) | 2.4 | 1.1-5.7 | .04 | 1.9 | 0.5-7.2 | .33 |
| BM involvement (by morphological assessment) | 32 (37) | 3.4 | 1.7-7.0 | <.001 | 3.8 | 0.8-19.0 | .10 |
| Other extranodal sites of involvement | 35 (40) | 2.1 | 1.0-4.2 | .04 | 1.0 | 0.2-4.5 | .96 |
| IPI score, n (%) | |||||||
| 0-1 (group 1) | 17 (20) | 1.0 | |||||
| 2 (group 2) | 28 (32) | 4.4 | 0.5-35.0 | .16 | 7.8 | 0.8-73.0 | .07 |
| 3 (group 3) | 30 (34) | 7.5 | 1.0-57.0 | .052 | 2.1 | 0.1-28.0 | .59 |
| 4-5 (group 4) | 12 (14) | 11.8 | 1.5-95.0 | .02 | 0.4 | 0.01-21.0 | .64 |
| PIT score, n (%) | |||||||
| 0-1 (group 1) | 44 (51) | 1.0 | |||||
| 2 (group 2) | 24 (28) | 2.1 | 0.8-5.2.0 | .13 | 0.8 | 0.2-3.5 | .76 |
| 3-4 (group 3) | 19 (22) | 4.3 | 1.8-10.0 | <.001 | 1.3 | 0.1-30.0 | .87 |
| Histology | |||||||
| PTCL-NOS | 28 (32) | 1.0 | |||||
| PTCL-TFH | 6 (7) | 1.0 | 0.2-4.3 | .95 | |||
| AITL | 39 (45) | 0.8 | 0.4-1.8 | .61 | |||
| ALK+ ALCL | 2 (2) | 0.0 | - | .99 | |||
| ALK− ALCL | 8 (9) | 0.3 | 0.04-2.4 | .26 | |||
| MEITL | 4 (5) | 0.9 | 0.1-7.1 | .93 | |||
| Use of etoposide-containing regimens | 47 (54) | 0.7 | 0.3-1.3 | .25 | |||
| Use of BV-containing regimens | 12 (14) | 1.9 | 0.6-6.5 | .31 | |||
| ASCT consolidation | 37 (43) | 0.2 | 0.1-0.5 | <.001 | 0.1 | 0.04-0.40 | < .001 |
| Maintenance therapy∗ | 12 (14) | 0.4 | 0.1-1.2 | .09 | |||
| TP53 mutation | 13 (15) | 0.7 | 0.2-1.9 | .45 | |||
| TP53 or 17p deletion | 5 (6) | 1.4 | 0.3-6.0 | .63 | |||
| CDKN2A deletion | 7 (8) | 5.3 | 1.9-14.4 | .001 | 12.1 | 2.8-52.0 | < .001 |
| TET2 mutation | 48 (55) | 1.3 | 0.6-2.7 | .47 | |||
| DNMT3A mutation | 17 (20) | 1.6 | 0.7-3.6 | .25 | |||
| DNMT3A exon 23 mutation | 5 (6) | 0.0 | - | .99 | |||
| RHOA mutation | 26 (30) | 0.9 | 0.4-2.0 | .79 | |||
| FAT1 mutation | 4 (5) | 1.9 | 0.4-8.1 | .40 | |||
| STAT3 mutation | 4 (5) | 1.1 | 0.2-8.5 | .90 | |||
| SETD2 mutation | 5 (6) | 0.0 | - | .99 | |||
| IDH2 mutation | 7 (8) | 2.0 | 0.7-5.8 | .19 | |||
| PCLG1 mutation | 7 (8) | 2.1 | 0.6-7.2 | .22 | |||
| Total number of aberrancies | 87 (100) | 1.0 | 1.0-1.1 | .04 | |||
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase.
Bold indicates P < .05.
∗
Twelve patients received maintenance systemic therapy on a clinical trial either after chemotherapy or after ASCT.